Dr. Nikolay Savchuk is the CEO of ChemDiv, Inc. (San Diego, CA) and Managing Partner at Torrey Pines Investment (San Diego, CA), Member of the Board of Directors, ChemRar High Tech Center (Moscow, Russia), and Chairman of the Board of Directors itscompanies: Chemical Diversity Research Institute, Viriom, NewVac, TeaRx, and SatRx.
Dr. Savchuk is a member of U.S.-Russian Bilateral Presidential Commission’s Working Group on Health, a member of the expert council of the Agency of Strategic Initiatives and New Projects of the Russian government, member on the board of the non-profit BioPharmClutster Northern, co-founder and member of the advisory board Initiative «PhysTech 21?, and the Director for Strategic Development of Moscow Institute of Physics and Technology (MIPT). Dr. Savchuk was a co-founder of the Inel Group of IT and media companies in Singapore and Russia, managing a number of its companies.
The scope of main interest of Dr. Savchuk is life sciences including rational drug design, drug discovery and digital health technologies. Dr. Savchuk lead and continues to manage successful investments in pharmaceutical and drug development companies.
Dr. Savchuk obtained the MS degree in physics in 1994 and Ph.D. in applied mathematics in 2000 from Moscow Institute of Physics and Technology. Results of his research are published in more than 100 scientific publications and patents. He frequently presented at numerous international conferences, including the American Chemical Society Meetings, Society of Biomolecular Screening, Drug Discovery Technologies, World Vaccine Congress, Open Innovations Summit, BIO International Convention, Pharmaceutical Strategic Alliances and other industrial, scientific and investment venues.